A Dose of Strong Medicine

P., Shankar
June 2003
njbiz;6/23/2003, Vol. 16 Issue 25, p35
Focuses on the financial performance of the pharmaceutical company Pfizer in New York City. Income posted by the company in 2002; Plans of the company for its business; Drugs that face the loss of their patents.


Related Articles

  • No magic potion among Pfizer's drugs. Harrington, John // Crain's New York Business;04/23/2001, Vol. 17 Issue 17, p46 

    Reports on an increase in the earnings of New York City-based pharmaceutical firm Pfizer Inc. for the first quarter of the year 2001. Factors behind the increase; Percentage of revenue growth achieved by the firm; Business strategies to further increase the firm's earnings.

  • Pfizer Offers Solid 3Q Results.  // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p3 

    Reports on the performance of pharmaceutical company Pfizer as of October 22, 2001. Factors contributing to Pfizer's strong performance; Net income of the company in the third quarter of 2001; Percentage of the market held by the Pfizer drug Lipitor.

  • Pfizer Maintains Steady 3Q Growth.  // Chemical Market Reporter;10/21/2002, Vol. 262 Issue 14, p3 

    Reports on the growth in profits of the pharmaceutical company Pfizer Inc. in the third quarter of 2002. Percentage rise in the company's earnings; Percentage rise in sales of the company; Drugs that contributed to higher sales.

  • Pfizer India Ltd.--implementing restructuring programme.  // Chemical Business;Mar1998, Vol. 12 Issue 3, p80 

    Focuses on the financial performance of Pfizer India Ltd., a pharmaceutical company, for the fiscal year that ended March 1997. Sales; Net profits; Earning per share.

  • Johnson & Johnson and Pfizer show strong earnings growth. Martinez, Marialba // Caribbean Business;4/25/2002, Vol. 30 Issue 17, p16 

    Reports on the financial performance of drug companies Johnson & Johnson and Pfizer Co. during the first quarter of 2002. Corporate profits; Sales; Growth targets and strategies.

  • Pfizer Continues to Dominate in Second Quarter. Jarvis, Lisa // Chemical Market Reporter;7/26/2004, Vol. 266 Issue 3, p8 

    Reports on the strong industrial performance of Pfizer Inc. with stable sales and earnings statistics for the second quarter of 2004 despite greater competition for several key drugs. Net income posted by Pfizer for the said period; Major competitors of Pfizer; Strong sales performance of its...

  • Medicine Man. McKinnell, Hank; Gibbs, Lisa // Money;Jun2001, Vol. 30 Issue 6, p37 

    Presents an interview with Henry McKinnell, chief executive officer of pharmaceutical company Pfizer. Competition between Pfizer's drug Lipitor and Astra-Zeneca's Crestor; Product launches planned for 2001; Reasons for a slower revenue growth in 2000.

  • PFIZER'S EARNINGS SURGE, DRUG FIRMS' GROWTH MODERATE.  // Caribbean Business;10/26/1995, Vol. 23 Issue 43, p58 

    Reports on the financial performance of Pfizer Inc. in the third quarter of 1995. Increase in earnings; Net income posted; Favorable exchange rates' addition of sales growth; Strong sales of products such as the antidepressant Zoloft and the heart medication Norvasc.

  • Akzo Nobel Strives to Boost Pharma With Pfizer Deal. Jarvis, Lisa // Chemical Market Reporter;11/3/2003, Vol. 264 Issue 15, p8 

    Reports on the agreement between the pharmaceutical firms Akzo Nobel Pharmaceutical and Pfizer Inc. in the U.S. Sales performance of Akzo Nobel; Benefits of the deal for the companies; Business strategies of Akzo Nobel.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics